[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Hospital Centre Biel\u002FBienne\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":47},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100533534","phase-2-precise-neoadjuvant-chemoresection-of-low-grade-nmibc-100533534",false,"NCT06227065","Precise Chemoresection in Low-grade NMIBC Using Drug Screens in Patient-derived Organoids","POLO-Trial. Precise Neoadjuvant Chemoresection of Low-grade NMIBC Guided by Drug Sceens in Patient-derived Or-ganoids. An Open-label, Phase II Trial.","POLO","Inclusion Criteria:\n\n1. Signed Informed Consent Form\n2. Age ≥ 18 years\n3. Primary or recurrent NMIBC suspected to be low-grade or maximum G2 with a negative urine cytology\n\nExclusion Criteria:\n\n1. Anticoagulation other than acetylsalicylic acid\n2. Evidence of significant uncontrolled concomitant disease that could affect compliance with the protocol as judged by the investigator\n3. Severe infection within 4 weeks prior to the date of the patient's informed consent signature\n4. Contraindication for frequent catheterization\n5. Pregnancy or nursing. Female subject of childbearing potential (defined as premenopausal women who have not undergone surgical sterilization and are sexually active with a male part-ner) must have a negative urine pregnancy test at screening\n6. Female subject of childbearing potential who is unwilling to use effective contraception method(s) from the start of the intravesical instillation with the IMP until six months after the last instillation\n7. Male subject who is unwilling to use an effective contraception method from the start of the intravesical instillation with the IMP until four months after the last instillation\n8. Vulnerable individual, e.g., individual incapable of judgement or currently incarcerated or oth-erwise institutionalized (prisoner), or refugee\n9. Concomitant participation in another interventional clinical trial with an active treatment within 4 weeks prior to the date of the patient's informed consent signature and during the current trial.","ALL","18 Years",{"count":20,"type":21},28,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","Based on the unmet clinical need to reduce invasiveness of treatment of low grade NMIBC, the investigators conduct this prospective, open label, single arm and single center phase II trial. The investigators aim to use drug screens in PDOs to guide neoadjuvant intravesical instillation therapy with either Epirubicin, Mitomycin C, Gemcitabine or Docetaxel to achieve chemoresection NMIBC.",[27,28,29],"Bladder Cancer","Non-muscle Invasive Bladder Cancer","Low Grade",[31,32,33],"Patient derived organoids","Neoadjuvant chemoresection","Precise drug selection","NOT_YET_RECRUITING","2026-09-15",{"date":37,"type":38},"2026-09-18","ACTUAL",{"date":40,"type":21},"2026-12-01",{"date":42,"type":21},"2031-11-30",{"name":44,"class":45},"Hospital Centre Biel\u002FBienne","OTHER",2,""]